COMMUNIQUÉS West-GlobeNewswire

Leading Independent Proxy Advisory Firm ISS Recommends Aeterna Zentaris and Ceapro Securityholders Vote FOR the Arrangement Agreement to Approve the Merger of Equals to Create a Diversified Biopharmaceutical Company
26/02/2024
ISS states in its Aeterna Zentaris FOR recommendation that “on balance, the deal has strong strategic merit, third party solicitation was unable to generate any other actionable proposals, and governance conflicts [...]
Orion Group Financial Statement documents 2023, Corporate Governance Statement and Remuneration Report published
26/02/2024
ORION CORPORATION STOCK EXCHANGE RELEASE – ANNUAL FINANCIAL REPORT 26 FEBRUARY 2024 at 14.30 EET Orion Group Financial Statement documents 2023, Corporate Governance Statement and Remuneration Report published Orion [...]
Kura Oncology Doses First Patient in KOMET-008 Trial of Ziftomenib in Combination with Standards of Care, Including FLT3 Inhibitor, in Acute Myeloid Leukemia
26/02/2024
– KOMET-008 is evaluating ziftomenib in combination with gilteritinib, FLAG-IDA or LDAC in patients with relapsed/refractory NPM1-mutant or KMT2A-rearranged AML – SAN DIEGO, Feb. 26, 2024 (GLOBE NEWSWIRE) -- Kura [...]
Anavex Life Sciences to Present at the 44th Annual TD Cowen Health Care Conference
26/02/2024
NEW YORK, Feb. 26, 2024 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of [...]
Allakos Presents Preclinical Data Highlighting Inhibition of MRGPRX2-Mediated Mast Cell Activation with AK006 at AAAAI 2024
26/02/2024
– Atopic dermatitis and prurigo nodularis skin lesions show evidence of MRGPRX2 mast cell activation and activated macrophages – – AK006 inhibited mast cell activation and reduced mast cell numbers in an MRGPRX2-induced [...]
Celldex Reports Fourth Quarter and Year End 2023 Financial Results and Provides Corporate Update
26/02/2024
- Phase 3 CSU studies expected to initiate in summer 2024 - - Positive Phase 2 CSU 12 week data reported in late breaking oral presentation at AAAAI 2024; 52 week data to be reported in 2H 2024 - - Enrollment nearing [...]
BioCryst Reports Fourth Quarter and Full Year 2023 Financial Results and Upcoming Key Milestones
26/02/2024
—ORLADEYO net revenue of $90.9 million for Q4 2023 and $326.0 million for FY 2023 (+30 percent y-o-y) — —2024 ORLADEYO net revenue expected to be between $380-$400 million— —Company expects operating profit in 2024, [...]
Mesoblast Financial Results and Corporate Update Webcast
26/02/2024
NEW YORK, Feb. 26, 2024 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, will host a webcast to discuss operational highlights and [...]
Transactions in connection with share buy-back program
26/02/2024
Company Announcement COPENHAGEN, Denmark; February 26, 2024 – Genmab A/S (Nasdaq: GMAB). On February 14, 2024, Genmab announced the initiation of a share buy-back program to honor our commitments under our Restricted [...]
Alvotech Accepts Offer for the Sale of Shares for a value of approximately USD 166 million at a Purchase price of USD 16.41 (ISK 2,250) per Share
26/02/2024
REYKJAVIK, Iceland, Feb. 26, 2024 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today announced [...]
Alvotech Accepts Offer for the Sale of Shares for a value of approximately USD 166 million at a Purchase price of USD 16.41 (ISK 2,250) per Share
26/02/2024
Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today announced that it has accepted an offer from investors (the “ [...]
Community Health Worker (CHW) Initiative Launched In New Hampshire
26/02/2024
North Country Health Consortium Works With Partners to Improve Health Outcomes In the State Littleton, NH, Feb. 26, 2024 (GLOBE NEWSWIRE) -- The state of New Hampshire has provided funding to North Country Health [...]
Zealand Pharma announces Boehringer Ingelheim survodutide Phase 2 trial shows 83% of adults treated achieved groundbreaking results in liver disease due to MASH, with significant improvements in fibrosis
26/02/2024
Company announcement - No. 8 / 2024 Zealand Pharma announces Boehringer Ingelheim survodutide Phase 2 trial shows 83% of adults treated achieved groundbreaking results in liver disease due to MASH, with significant [...]
Survodutide Phase II trial shows 83% of adults treated achieved groundbreaking results in liver disease due to MASH, with significant improvements in fibrosis
26/02/2024
Survodutide has potential to become best-in-class treatment for metabolic dysfunction-associated steatohepatitis (MASH)*, after meeting its primary and key secondary endpoint following 48 weeks of treatment versus [...]
IBA Notice of Full Year 2023 Results and Conference Call
26/02/2024
FY23 results meeting to take place as a hybrid event on Thursday, 21 March 2024 at 3pm CET Louvain-la-Neuve, Belgium, 26 February 2024 - IBA (Ion Beam Applications S.A., EURONEXT), the world leader in particle [...]
IBA : Publication des résultats annuels 2023 et conférence web
26/02/2024
La conférence sur les résultats annuels aura lieu le jeudi 21 mars 2024 à 15h00, heure de Bruxelles Louvain-la-Neuve, Belgique, le 26 février 2024 - IBA (Ion Beam Applications S.A.), le premier fournisseur mondial de [...]
argenx to Present at Upcoming Investor Conferences
26/02/2024
February 26, 2024 Amsterdam, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced that [...]
New England Journal of Medicine publishes Phase III data showing Xolair significantly reduced allergic reactions across multiple foods in people with food allergies
25/02/2024
Detailed results from the NIH-sponsored Phase III OUtMATCH study showed treatment with Xolair increased the amount of peanuts, tree nuts, egg, milk and wheat that people as young as 1 year consumed without an allergic [...]
Celldex Therapeutics Presents Positive 12 Week Results from Barzolvolimab Phase 2 Study in Chronic Spontaneous Urticaria
24/02/2024
- Primary and secondary endpoints met with clinically meaningful and statistically significant decreases in urticaria disease activity across multiple dose groups - - Sustained activity with rapid onset within 2 weeks [...]

Pages